Smart radiation seeks out lung cancer cells in new trial
NCT ID NCT06228482
First seen Mar 04, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This early-stage trial is testing a pair of radioactive drugs designed to find and attack non-small cell lung cancer that has spread. First, a scanning drug highlights tumors. Then, a therapeutic drug delivers radiation directly to those tumors. The study will enroll 40 adults whose cancer has worsened despite standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NONSMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radioactive drugs [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G
What this could lead to
If it works, this could offer a new targeted treatment option for people with advanced lung cancer that has spread.
What could go wrong
This is an early Phase 1 trial with only 40 people, so it's too soon to know if it works. The treatment involves radiation, which can cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.